Hi-Tech Pharmacal Co Inc (HITK.OQ)
|Market Cap (Mil.):||$590.16|
|Shares Outstanding (Mil.):||13.62|
- Generic drugmaker Akorn Inc will buy rival Hi-Tech Pharmacal Co Inc for $640 million to expand its eye drug portfolio to oral liquids and ointments.
Aug 27 - Specialty pharmaceutical company Akorn Inc will buy rival Hi-Tech Pharmacal Co Inc for $640 million in cash to expand its eye drug portfolio to other dosage forms such as oral liquids, topical creams and ointments.
|Wockhardt Limited (WCKH.NS)||Rs400.50||-2.20|
|Salix Pharmaceuticals, Ltd. (SLXP.OQ)||$84.01||-0.68|
|Impax Laboratories Inc (IPXL.OQ)||$23.68||-0.04|
|BioMarin Pharmaceutical Inc. (BMRN.OQ)||$69.62||-0.41|
|Akorn, Inc. (AKRX.OQ)||$25.31||-0.32|
|SciClone Pharmaceuticals, Inc. (SCLN.OQ)||$4.51||-0.05|
|Lannett Company, Inc. (LCI.A)||$31.00||-1.40|
|ISIS Pharmaceuticals, Inc. (ISIS.OQ)||$39.44||+0.80|
|POZEN Inc. (POZN.OQ)||$8.05||+0.11|
|Pain Therapeutics, Inc. (PTIE.OQ)||$4.45||-0.11|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of HI TECH PHARMACAL CO INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.